Analyst Downgrades: NeoPhotonics Corp, Cempra Inc, and Teva Pharmaceutical Industries Ltd

Analysts downwardly revised their ratings and price targets on NeoPhotonics Corp (NPTN), Cempra Inc (CEMP), and Teva Pharmaceutical Industries Ltd (ADR) (TEVA)

Kirra Fedyszyn
Dec 20, 2016 at 9:58 AM
facebook twitter linkedin


Analysts are weighing in on circuit maker NeoPhotonics Corp (NYSE:NPTN), as well as drug stocks Cempra Inc (NASDAQ:CEMP) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). Here's a quick roundup of today's bearish brokerage notes on NPTN, CEMP, and TEVA.

  • NPTN is plunging 10.4% to $11.19 after the company downwardly revised its fourth-quarter outlook, citing delayed shipments, while also announcing it will sell its low-speed transceiver business to APAT Optoelectronics Components Co. for $26.4 million. At least four analysts cut their price targets on the stock following the news, including B. Riley, which set the lowest bar, at $11. This morning's drop has NeoPhotonics Corp surrendering most of its year-to-date gains, giving up its foothold above the 320-day moving average. Short sellers could be cheering this price action, however. These bearish bets surged by nearly 43% during the most recent two-week reporting period, and now account for about 7% of NPTN's total float. 

  • SunTrust Robinson downgraded CEMP to "sell" all the way from "buy," and slashed its price target on the stock to $5 from $18 -- representing record-low territory for the shares. CEMP has slid 3.8% to $6.93 this morning, widening its year-to-date deficit to almost 78%. The equity has failed to make much upward progress since its huge drug-data-induced bear gap in early November, but it appears options traders had been banking on a comeback. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Cempra Inc saw 6.83 calls purchased for every put over the past 10 sessions. What's more, the resulting call/put volume ratio ranks higher than 71% of the past year's readings.

  • TEVA is 0.2% higher at $36.66 despite a price-target cut to $45 from $47 at Credit Suisse. Teva Pharmaceutical Industries Ltd has been sliding down the charts all year, dropping 44.2% in 2016, with the descending 30-day moving average providing pressure on the share since August. Should the stock resume this downward trend, more bearish attention from the brokerage bunch could send TEVA even lower. At present, more than half of the analysts following the security rate it a "buy" or better, and not one gives a "sell" recommendation. Moreover, the average 12-month price target of $59.20 sits at a 61.5% premium over current levels.
Find out where the Dow lands right after the closing bell. Sign up now for Schaeffer's Market Recap

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earnings guide for Q3 before it's too late!


  
 

Partnercenter